Gene stockI’m not that big with charts and showing where I place stuff but my prediction on this will be at 5$ Our support after that we will reach a new high to 10$ but struggle to climb upwards dude to the lack of stock revenue and profit income
Yellow line is why I bought in
Green line is my test for support
GTG trade ideas
Genetic Technologies USA Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series
Focus: Worldwide
By Sun Storm Investment Research & NexGen Wealth Management Service
A Profit & Solutions Strategy & Research
Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures |
USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India
Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision.
#debadipb #profitsolutions
$GENE $4.41 / $GTG $0.085GTGs US sister (GENE) received some decent attention overnight, GTG should follow thru at some stage.
US Covid test deal released 01/06/21
MC $72M
There are 9B SOI BUT largest holder has acquired 6.6B 73%
Long Opportunity $GENE WAIT PULLBACKLong Opportunity $GENE WAIT PULLBACK
Must be Patient with your Entry!!
If wrong cut loss quickly and move on - (4-5% Loss its Better than 20-21% Loss)
scenario (A)
3.85 Long Entry
under 3.7 STOP LOSS
6.3 Target Price
scenario (B)
2.9 to 3.15 Long Entry
under 2.7 STOP LOSS
6.3 Target Price
Long Opportunity $GENE WAIT PULLBACKLong Opportunity $GENE WAIT PULLBACK
Must be Patient with your Entry!!
If wrong cut loss quickly and move on - (4-5% Loss its Better than 20-21% Loss)
scenario (A)
3.85 Long Entry
under 3.7 STOP LOSS
6.3 Target Price
scenario (B)
2.9 to 3.15 Long Entry
under 2.7 STOP LOSS
6.3 Target Price
$GENE: SmlCap play - Potential 20-70% upside from today's closesee easy and self explanatory boxes on chart for Entry, Exit and Stop loss zones. Never chase any stock.
Not for any recommendation, Just an Idea. Like it >> Click 👍/comment, and follow.
BUY GENE - GENETIC TECHNOLOGIES - STRONG BUY ON WEEKLY CHARTBUY GENE - GENETIC TECHNOLOGIES - STRONG BUY ON WEEKLY CHART
$GENEGenetic Technologies Limited (NASDAQ:GENE) The daily chart looks great for this stock and I think it's poised to hit $4.65 short term as the selling has abated and the recent rally on BNGO stock should bring new interest into the stock. I think this stock has room to go to the upside with $4.04 being the first point of interest.
$GTG.asx - Price Bounced off 50% fibs and look good to continue $GTG.asx - Price Bounced off 50% fibs and look good to continue the trend reversal, indis and vol look good. Took a position, Let's see... GL
Please DYOR first... GL
GENE: Last Breakout was Crazy, High Volume Pop?GENE is one of those stocks that had support pickup for volume which lead to a really big breakout. The selloff was as bad, given many people getting excited can leave just as quick. I'm not sure I would consider it far enough evidence yet for market manipulation. That being said, even with lots of the resistance it has been receiving, I think it has potential for a positive retest. I would rate this as mid risk, but think that bullish correlations can push this past the $7 price point quite soon. That being said, please do your own due diligence. Invest at your own risk. Everything I say is on an opinion based basis.
GENE possible trend on mondayThis is simple charting representing the trend of GENE. The trend seem to be upward the resistance is at 7$ and support is seem to be below from the current price levels, this charting is only my opinion and based on trend lines and support and resistance
GENE - high volume and elliott wave lookoutHigh volume could see impulse go higher after correction to $40 zone
31 rules that keeps you safe and profitable .I think you get the point of this .
I made killing on this today and I followed the rules especially #26 was the key today .
Update on COVID-19 Disease Severity TestGenetic Technologies Provides Update on COVID-19 Disease Severity Test
Highlights
-Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in Australia
-The COVID-19 Severity Risk Test comprises a polygenic risk test (PRS) and assessment for clinical risk factors
-Genetic Technologies has completed the design and request for initial production of the SNP (Single Nucleotide Polymorphism) panel required to process the polygenic risk test portion of the COVID-19 Severity Risk Test from US-based Thermo Fisher Scientific
-Genetic Technologies has confirmed with major manufacturers that the COVID-19 Severity Risk Test, including a reagent and SNP panel, is capable of being rolled out on a large scale
-Discussions held with Centres for Medicare and Medicaid Services (CMS) and National Association of testing Authorities, Australia (“NATA”) for regulatory Approval for the COVID-19 Severity Risk Test in the United States and Australia
Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with IP Australia (2020901739 – Methods of assessing risk developing a severe response to Coronavirus infection)
www.globenewswire.com
Furthermore, the company has confirmed capacity to scale up production for a global-roll out of the COVID-19 test (reagent and SNP panel) with major manufacturers.
The Company's Australian facilities will have the capacity of producing up to 250,000 tests per year. The scale-up of manufacturing will require global distribution partnerships if COVID-19 Severity Risk Test is widely adopted.
GENE is in discussion with the respective regulatory authorities for approval of COVID-19 Severity Risk Test in the U.S. and Australia.
seekingalpha.com
$GENE Genetic Technologies Ltd.long above $2.55Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia
Gene uptrend channel initiated in April 2020Short term uptrend channel should hit a maximum around 3.84 before the big news
